Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07553299 · ClinicalTrials.gov registry record · Phase 2
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A Phase 2 study, sponsored by Verdiva Bio Dev Limited.
- Not yet
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT07553299: Clinical Trial Phase 2 study, sponsored by Verdiva Bio Dev Limited.
NCT07553299 is a Phase 2 study that has not yet begun recruiting, run by Verdiva Bio Dev Limited. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07553299, a Phase 2 study, has not yet begun recruiting, sponsored by Verdiva Bio Dev Limited.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
Interventions
- DRUG Placebo
- DRUG VRB-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-06 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07553299
The ClinicalTrials.gov registry entry for NCT07553299 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verdiva Bio Dev Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07553299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07553299 about?
NCT07553299 is a clinical study titled "A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities". The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
What is the current status of trial NCT07553299?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-06. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT07553299?
The interventions under investigation include: Placebo (DRUG), VRB-101 (DRUG).
Who is sponsoring clinical trial NCT07553299?
This trial is sponsored by Verdiva Bio Dev Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.